Providence COVID-19 Vaccine Development - Stage 2
$8,600,000.00
Grant Value
2021-22
Fiscal Year
Description
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Providence Therapeutics Holdings Inc.
Location
Calgary, AB T2Z 3P4
Agreement Details
Number: 976618
Reference: 172-2021-2022-Q2-976618
Timeline
Start: July 23, 2021
End: Nov. 30, 2022
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (3254)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share